Comparative Pharmacology
Head-to-head clinical analysis: CARDENE versus PROCARDIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE versus PROCARDIA.
CARDENE vs PROCARDIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
20-40 mg orally three times daily.
Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
2-5 hours in healthy adults; up to 6-10 hours in cirrhotic patients or elderly; clinical context: requires extended-release formulations for once-daily dosing.
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via bile); 0% unchanged in urine.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker